MYXOID LIPOSARCOMA
Clinical trials for MYXOID LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new MYXOID LIPOSARCOMA trials appear
Sign up with your email to follow new studies for MYXOID LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a booster shot for immune cells fight rare sarcomas?
Disease control Recruiting nowThis early study tests an immunotherapy drug called N-803 in 8 people with rare soft-tissue sarcomas (synovial sarcoma or myxoid/round cell liposarcoma) whose cancer got worse after a prior cell therapy. N-803 aims to wake up leftover immune cells from the earlier treatment so th…
Matched conditions: MYXOID LIPOSARCOMA
Phase: EARLY_PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 26, 2026 03:35 UTC
-
New virus therapy aims to boost immune attack on hard-to-treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called PeptiCRAd-1, a virus designed to train the immune system to attack cancer cells, combined with the immunotherapy drug pembrolizumab. About 15 adults with certain advanced solid tumors (like melanoma, lung cancer, or sarcoma) wil…
Matched conditions: MYXOID LIPOSARCOMA
Phase: PHASE1 • Sponsor: Valo Therapeutics Oy • Aim: Disease control
Last updated May 26, 2026 03:32 UTC
-
Last-Chance therapy: expanded access offers TECELRA® to sarcoma patients who missed commercial specs
Disease control AVAILABLEThis program gives patients with synovial sarcoma or myxoid liposarcoma access to a cell therapy (TECELRA®) that didn't meet commercial quality standards. It's for people who have no other options for re-manufacturing or cell collection. The goal is to provide treatment when stan…
Matched conditions: MYXOID LIPOSARCOMA
Sponsor: USWM CT, LLC • Aim: Disease control
Last updated May 26, 2026 03:31 UTC
-
New combo therapy aims to halt rare cancer growth
Disease control Recruiting nowThis study tests whether two drugs, mirdametinib and palbociclib, can safely control advanced liposarcoma that has spread or cannot be removed by surgery. About 54 adults with this rare cancer will receive different doses to find the best balance of safety and effectiveness. The …
Matched conditions: MYXOID LIPOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC